PURPOSE: To develop a decisional instrument for ancestry-based cystic fibrosis and/or hemoglobinopathies carrier couple screening in The Netherlands. METHODS: A flowchart (Instrument A) and a questionnaire with maps of geographical areas with originally high cystic fibrosis and hemoglobinopathies carrier frequencies (Instrument B), were developed to support participants in self-assessing their eligibility as a couple for carrier screening for cystic fibrosis and/or hemoglobinopathies. The outcome was compared to the self-reported origin of both partners' ancestors during an in-depth interview. Furthermore, preference for Instrument A or B was determined. RESULTS: Of the 112 participants, 88% (99/112, 95% CI 82-94%) (Instrument A) and 91% (102/112, 95% CI 86-96%) (Instrument B), respectively, arrived at a decision in accordance with their ancestral origin, and 57% (64/112, 95% CI 48-66%) preferred Instrument B. A false negative proportion of 5.5% suggests that some carriers will exclude themselves from screening. Results might improve with minor changes in the instruments with regard to geographic specification, and availability of translated versions. CONCLUSION: A decisional instrument to assess ancestry-based eligibility for cystic fibrosis and/or hemoglobinopathies carrier screening, is now available and can with slight adaptations be used in other countries. The instrument also takes into account the possibility of mixed ancestry.
PURPOSE: To develop a decisional instrument for ancestry-based cystic fibrosis and/or hemoglobinopathies carrier couple screening in The Netherlands. METHODS: A flowchart (Instrument A) and a questionnaire with maps of geographical areas with originally high cystic fibrosis and hemoglobinopathies carrier frequencies (Instrument B), were developed to support participants in self-assessing their eligibility as a couple for carrier screening for cystic fibrosis and/or hemoglobinopathies. The outcome was compared to the self-reported origin of both partners' ancestors during an in-depth interview. Furthermore, preference for Instrument A or B was determined. RESULTS: Of the 112 participants, 88% (99/112, 95% CI 82-94%) (Instrument A) and 91% (102/112, 95% CI 86-96%) (Instrument B), respectively, arrived at a decision in accordance with their ancestral origin, and 57% (64/112, 95% CI 48-66%) preferred Instrument B. A false negative proportion of 5.5% suggests that some carriers will exclude themselves from screening. Results might improve with minor changes in the instruments with regard to geographic specification, and availability of translated versions. CONCLUSION: A decisional instrument to assess ancestry-based eligibility for cystic fibrosis and/or hemoglobinopathies carrier screening, is now available and can with slight adaptations be used in other countries. The instrument also takes into account the possibility of mixed ancestry.
Authors: Phillis Lakeman; Anne Marie Catharina Plass; Lidewij Henneman; Pieter Dirk Bezemer; Martina Cornelia Cornel; Leo Pieter ten Kate Journal: Eur J Hum Genet Date: 2009-02-18 Impact factor: 4.246
Authors: Suze M P J Jans; Ank de Jonge; Lidewij Henneman; Martina C Cornel; Antoinette L M Lagro-Janssen Journal: Eur J Hum Genet Date: 2012-05-02 Impact factor: 4.246
Authors: Suze M P J Jans; Carla G van El; Eddy S Houwaart; Marjan J Westerman; Rien J P A Janssens; Antoinette L M Lagro-Janssen; Anne Marie C Plass; Martina C Cornel Journal: Ethn Health Date: 2011-08-08 Impact factor: 2.772
Authors: S M P J Jans; L Henneman; A de Jonge; C G van El; L H van Tuyl; M C Cornel; A L M Lagro-Janssen Journal: Fam Pract Date: 2013-04-29 Impact factor: 2.267
Authors: Stephanie S Weinreich; Elly Sm de Lange-de Klerk; Frank Rijmen; Martina C Cornel; Marja de Kinderen; Anne Marie C Plass Journal: BMC Public Health Date: 2009-09-15 Impact factor: 3.295
Authors: Sylvia M van der Pal; Nicole M C van Kesteren; Jacobus P van Wouwe; Paula van Dommelen; Symone B Detmar Journal: J Environ Public Health Date: 2013-11-17